Eurofins Technologies (Paris:ERF) and Eurofins Genomics are pleased to announce the launch of two validated assays for the identification of B.1.1.7 (UK) and B.1.351 (South Africa) variants with a short turn-around time.
Eurofins Technologies (Paris:ERF) and Eurofins Genomics are pleased to announce the launch of two validated assays for the identification of B.1.1.7 (UK) and B.1.351 (South Africa) variants with a short
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
OraSure’s OMNIgene®·ORAL Saliva Collection Kit Selected by Chronomics for Use in UK Government .
OraSure Technologies, Inc.January 26, 2021 GMT
BETHLEHEM, Pa., Jan. 26, 2021 (GLOBE NEWSWIRE) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Chronomics Limited has selected the OMNIgene®·ORAL (OME-505) saliva collection device as a component of its SARS CoV-2 PCR test. Chronomics Limited will supply its test for the United Kingdom’s “Test to Release for International Travel” program. The OMNIgene®·ORAL device is a product of OraSure’s DNA Genotek subsidiary.
Ã
Expand
The breath biomarker panel, which is now commercially available, is intended to support research to distinguish between different types of chronic inflammatory airway diseases including asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF), and to facilitate better therapeutic decision making and monitoring.
Owlstone Medicalâs Respiratory Diseases RUO Panel consists of a set of biologically relevant Volatile Organic Compounds (VOCs) that have been linked to inflammatory respiratory diseases and can be easily collected on breath to enable direct characterisation of disease biology in the lungs by non-invasively sampling the airways.Â
Available as an early output from the companyâs test development process and supported by scientific publications and Breath Biopsy client study data, the Panel will initially be offered for Research Use Only as part of an expanded Breath Biopsy Products and Services offering
Eurofins launches new tests and massive capacity for detecting and monitoring new variants of SARS-CoV-2
Friday, January 15, 2021
The increasing diversity of SARS-CoV-2 variants and the potential higher infectivity of some new viral strains, underline the need to identify, trace and track mutations across the complete viral genome. Currently, strains of concern include the B.1.1.7 variant, first identified in the United Kingdom, and the B.1.351 variant, first identified in South Africa.
Eurofins is pleased to announce the following initiatives to support health authorities variant detection and monitoring programmes:
Increasing, to more than 5,000 full genomes per day, the capacity for its ARTIC Next Generation Sequencing (NGS)